Return on Equity (ROE): Regeneron Pharmaceuticals's financial strength is reflected in its exceptional ROE, which exceeds ...

Shares of Regeneron Pharmaceuticals, Inc. REGN have lost 22.6% year to date against the industry’s growth of 0.6%. The stock ...

Buying $1000 In REGN: If an investor had bought $1000 of REGN stock 20 years ago, it would be worth $57,109.53 today based on a price of $563.10 for REGN at the time of writing.

Longleaf Partners, managed by Southeastern Asset Management, released its “Partners Fund” second-quarter 2025 investor letter ...

Regeneron Pharmaceuticals has a price-to-sales (P/S) ratio of 4.6 versus a figure of 3.0 for the S&P 500 Moreover, the company’s price-to-free cash flow (P/FCF) ratio stands at 16.4 in contrast ...

The fall of 23andMe and its acquisition by Regeneron represents more than just one company’s business failure—it potentially signals a fundamental shift in the direct-to-consumer genetic ...

Regeneron said in its statement that as the named buyer in the bankruptcy auction, it “intends to ensure compliance” with 23andMe’s privacy policies and laws regarding customer data.